0001209191-23-037091.txt : 20230614
0001209191-23-037091.hdr.sgml : 20230614
20230614170649
ACCESSION NUMBER: 0001209191-23-037091
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230614
FILED AS OF DATE: 20230614
DATE AS OF CHANGE: 20230614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Duncan Barbara Gayle
CENTRAL INDEX KEY: 0001353128
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39344
FILM NUMBER: 231014941
MAIL ADDRESS:
STREET 1: C/O INTERCEPT PHARMACEUTICALS, INC.
STREET 2: 18 DESBROSSES STREET
CITY: NEW YORK
STATE: NY
ZIP: 10013
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fusion Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001805890
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 270 LONGWOOD ROAD SOUTH
CITY: HAMILTON
STATE: A6
ZIP: L8P 0A6
BUSINESS PHONE: 289-799-0891
MAIL ADDRESS:
STREET 1: 270 LONGWOOD ROAD SOUTH
CITY: HAMILTON
STATE: A6
ZIP: L8P 0A6
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-14
0
0001805890
Fusion Pharmaceuticals Inc.
FUSN
0001353128
Duncan Barbara Gayle
C/O FUSION PHARMACEUTICALS, INC.
2 INTERNATIONAL PLACE, SUITE 2310
BOSTON
MA
02110
1
0
0
0
0
Stock Opion (Right to Buy)
4.64
2023-06-14
4
A
0
17000
0.00
A
2033-06-13
Common Stock
17000
17000
D
This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc.
/s/Maria Stahl as Attorney-in-Fact for Barbara Duncan
2023-06-14